Growth factors: Do they play a role in entheseal involvement in psoriatic arthritis and undifferentiated spondyloarthritis patients?

Publication date: June–July 2021Source: Reumatología Clínica (English Edition), Volume 17, Issue 6Author(s): Cinzia Rotondo, Daniela Cici, Francesco Paolo Cantatore
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research

Related Links:

It feels like a long decade has passed since March 2020. At The Rheumatologist, we closed out 2020 with a special supplement on gout. Physician Editor Phil Seo, MD, MHS, kicked off that supplement with, “COVID-19. Black Lives Matter. A new gout guideline. These are some of the things 2020 ushered in. And we’re unlikely... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions PsA Resource Center Psoriatic Arthritis Source Type: research
The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions PsA Resource Center Psoriatic Arthritis tapering Source Type: research
We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Biologics & Biosimilars Conditions DMARDs & Immunosuppressives PsA Resource Center Psoriatic Arthritis Source Type: research
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Drug Updates Safety adalimumab PsA Resource Center Psoriatic Arthritis upadacitinib Source Type: research
Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Drug Updates Safety adalimumab PsA Resource Center Psoriatic Arthritis upadacitinib Source Type: research
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Patient Perspective Rheumatoid Arthritis Disease Activity Score (DAS) patient centeredness shared decision making Speak Out Rheumatology Treat-to-Target Source Type: research
Immunotherapy, Ahead of Print.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Drug Updates Guidelines PsA Resource Center Psoriatic Arthritis Source Type: research
Acta Derm Venereol. 2021 Oct 13. doi: 10.2340/actadv.v101.352. Online ahead of print.NO ABSTRACTPMID:34642767 | DOI:10.2340/actadv.v101.352
Source: Acta Derm Venereol A... - Category: Dermatology Authors: Source Type: research
Conditions:   Psoriatic Arthritis;   Foot Arthritis Intervention:   Device: Custom foot orthoses Sponsor:   Patrick Boissy Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arthritis | Psoriatic Arthritis | Rheumatology